Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
“Arthralgia Grade 2 60 (18) 1 (<1) Grade 3 11 (3) 2 (<1) Rash Grade 2 33 (10) 0 Grade 3 28 (8) 0 Fatigue Grade 2 38 (11) 33 (12) Grade 3 6 (2) 5 (2) Cutaneous squamous-cell carcinoma‡ Grade 3 40 (12) 1 (<1) Keratoacanthoma§ Grade 2 7 (2) 0 Grade 3 20 (6) 0 Nausea Grade 2 25 (7) 32 (11) Grade 3 4 (1) 5 (2) Alopecia Grad…”
Initial sequencing and comparative analysis of the mouse genome
Mouse Genome Sequencing Consortium (2002) · Nature · doi:10.1038/nature01262 · Cited by 7,187
Self-citation
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutations of the BRAF gene in human cancer. https://app.cochat.ai/papers/10.1038/nature00766
- The paper
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., . . . Futreal, P. A. (2002). Mutations of the BRAF gene in human cancer. Nature. https://doi.org/10.1038/nature00766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.